By Sunday 
New York bets on Adbert Alzolay’s potential to bolster their bullpen in 2026.
Mets Take a Gamble on Alzolay’s Recovery
The New York Mets are making headlines with a calculated gamble, signing former Chicago Cubs closer Adbert Alzolay to a two-year minor league deal. Once a dominant force in 2023 with a 2.67 ERA and 22 saves, Alzolay’s career was derailed by a forearm injury that required Tommy John surgery in 2024. Despite his recent struggles, the Mets see promise in the 28-year-old’s high ceiling.
According to The Athletic’s Will Sammon, the contract reflects the Mets’ long-term outlook. Alzolay is expected to miss most, if not all, of the 2025 season as he rehabilitates from surgery. However, the team’s investment in a two-year deal signals their belief in his potential to return stronger in 2026.
2025: A Year of Rehab and Possibility
While Alzolay is unlikely to contribute on the mound in 2025, the Mets haven’t entirely ruled out a late-season appearance if his recovery progresses faster than expected. For now, the focus remains on a full recovery, ensuring he regains his velocity and control—traits that made him a standout closer during his peak.
The Mets’ decision reflects a forward-thinking approach, valuing long-term gains over immediate impact. With Alzolay’s fastball averaging over 95 mph at its best, the potential payoff in 2026 could be significant.
Building for 2026 and Beyond
Alzolay’s return to full health in 2026 will be pivotal. If he can return to his pre-injury form, the Mets could secure a versatile bullpen weapon at a bargain. His career 4.04 ERA in various roles demonstrates his adaptability, whether as a closer or a middle reliever.
This signing also underscores the Mets’ commitment to balancing present needs with future aspirations. Elite organizations recognize the value of investing in talent with long-term potential, even when immediate results are uncertain.
A Worthwhile Risk for the Mets
While the 2025 Mets might not see much from Alzolay, the deal reflects a broader strategy of building a resilient bullpen for the years ahead. Moves like these often pay dividends for teams willing to take a chance on recovering talent.
For Alzolay, the Mets offer an opportunity to restart his career with a franchise that believes in his ability to bounce back. Should he return to his dominant form, this deal could prove to be one of the savviest low-risk, high-reward signings in recent memory.